State Street’s Obsidian Therapeutics OBX Stock Holding History

State Street’s Portfolio OBX Stock Details OBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.07M	Buy	+223,487	New	+$4.37M	﹤0.01%	3272

Other funds holding OBX

Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aster Capital Management Dubai, United Arab Emirates $275M AUM 18.46% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

State Street's OBX Position: Q3 2026 in Review

State Street opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 223,487 shares worth $3.07M. The stake represents ﹤0.01% of the portfolio and ranks #3272 among its holdings.

13 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

State Street held 223,487 shares of Obsidian Therapeutics worth $3.07M as of Q3 2026.
Obsidian Therapeutics was a new State Street position in Q3 2026.
Obsidian Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3272 holding.
13 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.